CD274 and neoplasm: Immune checkpoint blockade with anti-PD-L1 therapies that overcome tumor-mediated local immunosuppression have been shown to induce regression in 13–38% of metastatic TNBCs that are PD-L1 + by immunohistochemistry (IHC) staining29–31.